Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 31;7(1):e12226.
doi: 10.1002/trc2.12226. eCollection 2021.

The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives

Christopher J Weber  1 , Maria C Carrillo  1 , William Jagust  2 , Clifford R Jack Jr  3 , Leslie M Shaw  4 , John Q Trojanowski  5 , Andrew J Saykin  6 , Laurel A Beckett  7 , Cyrille Sur  8 , Naren P Rao  9 , Patricio Chrem Mendez  10 , Sandra E Black  11 , Kuncheng Li  12 , Takeshi Iwatsubo  13 , Chiung-Chih Chang  14 , Ana Luisa Sosa  15 , Christopher C Rowe  16 , Richard J Perrin  17 , John C Morris  18 , Amanda M B Healan  19 , Stephen E Hall  1 , Michael W Weiner  20
Affiliations

The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives

Christopher J Weber et al. Alzheimers Dement (N Y). .

Abstract

The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW-ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public-private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI-1, ADNI-GO, ADNI-2, and ADNI-3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW-ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW-ADNI researchers who shared updates from ADNI-3 and their vision for ADNI-4.

Keywords: Alzheimer's disease; MRI; PET; Tau; amyloid; biomarkers; cerebrospinal fluid; cognitive impairment; neuroimaging.

PubMed Disclaimer

Conflict of interest statement

WJ has served as a consultant to Bioclinica, Biogen, CuraSen, Grifols, and Roche/Genentech. CRJ serves on an independent data monitoring board for Roche, has served as a speaker for Eisai, and consulted for Biogen, but he receives no personal compensation from any commercial entity. He receives research support from NIH, the GHR Foundation, and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. AJS and the Indiana University ADRC receives in‐kind PET precursor support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly. CS is a full‐time employee of Merck and Co., Inc. and owns shares in the company. CCR has received institutional research grants from Cerveau Technologies, Biogen, Eisai, Abbvie, Roche, and Janssen, and is also participating in Scientific Advisory Boards for Cerveau Technologies and Biogen Australia. LMS is supported by the NIA ADNI‐3 grant for which he provides QC oversight for CSF analyses using the Roche Elecsys automated platform and reagents, and has also received IIS grant support for AD biomarker studies from Roche.

Figures

FIGURE 1
FIGURE 1
ADNI‐1 through ADNI‐4 timeline
See this image and copyright information in PMC

References

    1. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC. The Alzheimer's disease neuroimaging initiative: a review of papers published since its inception. Alzheimers Dement. 2013;9(5):e111–e194. 10.1016/j.jalz.2013.05.1769 - DOI - PMC - PubMed
    1. Mueller SG, Weiner MW, Thal LJ, et al. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am. 2005;15:869–877. 10.1016/j.nic.2005.09.008 - DOI - PMC - PubMed
    1. Mueller SG, Weiner MW, Thal LJ, et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's disease neuroimaging initiative. Cognition Dement. 2006;5:56–62. 10.1016/j.jalz.2005.06.003 - DOI - PMC - PubMed
    1. Weiner MW, Aisen PS, Jack CR, et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. 2010;6(3):202–211. 10.1016/j.jalz.2010.03.007. e7. - DOI - PMC - PubMed
    1. Jack CR Jr, Bernstein MA, Borowski BJ, et al. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement. 2010;6(3):212–220. 10.1016/j.jalz.2010.03.004 - DOI - PMC - PubMed